A number of other research firms have also recently weighed in on DBVT. JMP Securities lowered their price objective on DBV TECHNOLOGIE/S from $20.00 to $10.00 in a research report on Tuesday, March 17th. Stifel Nicolaus reissued a hold rating on shares of DBV TECHNOLOGIE/S in a research report on Friday, June 26th. Citigroup lowered their price target on DBV TECHNOLOGIE/S from $14.00 to $10.00 and set a buy rating for the company in a research report on Monday, April 6th. ValuEngine raised DBV TECHNOLOGIE/S from a hold rating to a buy rating in a research report on Wednesday, March 11th. Finally, SVB Leerink reaffirmed an outperform rating on shares of DBV TECHNOLOGIE/S in a research report on Wednesday, March 4th. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. DBV TECHNOLOGIE/S has an average rating of Buy and an average target price of $10.21.
DBV TECHNOLOGIE/S stock opened at $4.63 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.79 and a quick ratio of 3.75. The stock has a market capitalization of $481.14 million, a price-to-earnings ratio of -1.99 and a beta of 2.60. DBV TECHNOLOGIE/S has a 1-year low of $2.02 and a 1-year high of $13.49. The business has a fifty day moving average price of $5.16 and a 200-day moving average price of $7.37.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Further Reading: What is a front-end load?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.